The present disclosure provides modified immune cells or precursors thereof (e.g., gene edited modified T cells) comprising a modification in an endogenous gene locus encoding SOX and/or ID3. Methods for assessing and treating T cell dysfunction are also provided.

The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.

Modified cells comprising a transmembrane polypeptide comprising at least one extracellular target receptor-binding domain, a transmembrane domain and an intracellular domain, wherein said intracellular domain is not capable of transducing any signal are provided. Methods of inducing or inhibiting signaling by a target receptor in a target cell comprising contacting the target cell with a modified cell of the invention are also provided.

A cell comprising a mutant protein, the mutant protein causing the cell to be insensitive toward an inhibitor which affects the activity and; or killing function thereof; a universal chimeric antigen receptor T cell which is related to the cell and which is suitable for administration to non-specific patients; and a method for preparing the described cells and an application of the cells in cell therapy.

The present disclosure generally relates to, inter alia, an isolated recombinant cell overexpressing a SLP-76 polypeptide. The disclosure also provides compositions and methods useful for producing the isolated recombinant cells and the corresponding SLP-76 molecules, as well as methods for treatment of diseases, such as cancer, with such compositions.

The invention pertains to bispecific antibodies having two antigen binding specificities, one binding to an epitope of NKG2-D type II integral membrane protein (NKG2D) and one binding to an antigen associated with a disease, preferably a tumor associated- or tumor specific antigen, such as ErbB2 (HER2), CD19, CD20, GD2, PD-L1, EGFR, or EGFRvIII. The bispecific molecules of the invention are preferably applied in the context of the treatment of tumor diseases or infectious diseases. Surprisingly it was found that the use of NKG2D binding specificities that bind in a competitive manner to the NKG2D receptor with its natural ligands such as MICA reduces or prevents the inhibitory effect of ligand shedding. Another advantage of the present invention lies in a synergistic combination of the bispecific molecules of the invention and chimeric antigen receptor (CAR) based therapy. Further provided are methods for the production of the antibodies of the invention, nucleic acids encoding the bispecific antibodies or fragments thereof, pharmaceutical composition and recombinant cells comprising nucleic acids or antibody proteins.

Chimeric receptors are provided. Accordingly, there is provided a chimeric receptor comprising an extracellular binding domain and a heterologous amino acid sequence capable of recruiting a co-receptor comprising an intracellular signaling domain, such that upon binding of the extracellular binding domain to its target the signaling is transmitted in a cell expressing the chimeric receptor and the co-receptor. Also provided are protein complexes comprising the receptors, cells expressing same and uses thereof.

Provided herein are methods, compositions, and uses for treating subjects with diseases and conditions, such as those involving or associated with B cell maturation antigen (BCMA). In some aspects, the present disclosure relates to certain combination therapies that include administration of a cell therapy, such as a BCMA-targeted T cell therapy, in combination with immunomodulatory agents and other agents, such as dexamethasone, including for the treatment of subjects with multiple myeloma. In some embodiments, the multiple myeloma is a relapsed or refractory multiple myeloma.

The present invention provides compositions comprising chimeric receptors, including chimeric costimulatory receptors (CCRs), and/or chemokine receptors, methods for preparing CCRs and/or chemokine receptors, and therapeutic populations of tumor infiltrating lymphocytes, marrow infiltrating lymphocytes, and peripheral blood lymphocytes expressing CCRs and/or chemokine receptors with increased therapeutic performance and other advantages for the treatment of cancers, including solid tumor cancers.

The present invention belongs to the field of biological medicines, and particularly relates to a chimeric receptor for improving the killing activity of immune cells and an application thereof. Specifically, the present invention provides a fusion protein. The fusion protein comprises an extracellular part, an extracellular hinge region, a transmembrane region, and an intracellular region. Most preferably, the amino acid sequence of the fusion protein of the present invention is formed by sequentially connecting SEQ ID NO.: 1, SEQ ID NO.: 3, SEQ ID NO.: 5, SEQ ID NO.: 7, SEQ ID NO.: 9 and SEQ ID NO.: 11, and the immune cells expressing the fusion protein have strong killing activity.